The False Claims Act and the Policing of Promotion Claims About Drugs: A Call for Increased Transparency

77 Pages Posted: 19 Oct 2015

See all articles by Charles A. Sullivan

Charles A. Sullivan

Seton Hall University - School of Law

Kathleen Boozang

Seton Hall School of Law; Seton Hall University - Center for Health & Pharmaceutical Law & Policy

Kate Greenwood

Seton Hall University

Date Written: September 15, 2015

Abstract

The intersection of the False Claims Act with the FDA rules restricting the promotion of off-label uses of approved drugs has generated a confusing blend of public and private enforcement, primarily through settlements that provide little hard law. Many question whether this multi-billion dollar enforcement regime achieves its public policy goals. This white paper comprehensively describes how a False Claims Act case evolves, especially with regard to the relationship between the U.S. Department of Justice and the multiple interested federal and state agencies. While the traditional off-label promotion case may be waning, the white paper predicts and analyzes the next frontier of off-label enforcement – the provision of pharmacoeconomics information to pharmacy benefit managers, payers, and provider organizations. The paper draws from a thorough review of the cases, literature and numerous interviews with players in all sectors of the enforcement space, and exhaustively canvasses the challenges for all parties in reaching appropriate policy solutions. It ultimately recommends transparency, both in what is (and is not) "promotion" and in enforcement. The latter recommendations address both government sharing of information with qui tam relators when it does not assume control of a case and disclosure of the government's rationale for the remedies it seeks in negotiating settlements.

Keywords: fda, off-label, FCA, false claims act, promotion, drugs, pharmaceutical, qui tam, relator, Inspector General

Suggested Citation

Sullivan, Charles A. and Boozang, Kathleen M. and Greenwood, Kate, The False Claims Act and the Policing of Promotion Claims About Drugs: A Call for Increased Transparency (September 15, 2015). Available at SSRN: https://ssrn.com/abstract=2674670 or http://dx.doi.org/10.2139/ssrn.2674670

Charles A. Sullivan

Seton Hall University - School of Law ( email )

One Newark Center
Newark, NJ 07102-5210
United States
973-642-8870 (Phone)

Kathleen M. Boozang (Contact Author)

Seton Hall School of Law ( email )

One Newark Center
Newark, NJ 07102-5210
United States

Seton Hall University - Center for Health & Pharmaceutical Law & Policy ( email )

One Newark Center
Newark, NJ 07102-5210
United States

Kate Greenwood

Seton Hall University ( email )

400 S Orange Avenue
South Orange, NJ 07079
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
111
Abstract Views
773
rank
296,476
PlumX Metrics